Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Perhexiline maleate is an antianginal agent which depends on hepatic oxidation for its elimination. Its use may be complicated by the development of peripheral neuropathy and liver damage. The majority of patients with perhexiline neuropathy have an impaired ability to effect metabolic drug oxidation which is genetically determined. Information has not been available on drug oxidation capacity in patients with perhexiline liver injury. Drug oxidation was measured using an oxidation phenotyping procedure in four patients with perhexiline liver injury and in 70 patients with chronic liver disease serving as a control group. All four patients with perhexiline liver damage showed a substantial metabolic defect; three of the four patients (75%) showed a genetically determined impairment of oxidation capacity. The incidence of severely impaired oxidation capacity in the perhexiline group was significantly greater than in the patients with chronic liver disease (6/70; 8.6%) and in the healthy population (9%) (F = 0.0048). A clear association exists between perhexiline liver injury and diminished drug metabolic activity, suggesting that the propensity to develop perhexiline liver injury is, at least in part, genetically determined.

[1]  V. Beral,et al.  PREGNANCY OUTCOME IN INSULIN-DEPENDENT DIABETICS WITH THYROID DISEASE OR PERNICIOUS ANAEMIA , 1984, The Lancet.

[2]  R. Rowland,et al.  Perhexiline Maleate Induced Cirrhosis , 1983, Pathology.

[3]  C. Moulder,et al.  PERHEXILINE HEPATITIS AND HLA B8 , 1982, The Lancet.

[4]  M. Brodie,et al.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. , 1982, British journal of clinical pharmacology.

[5]  J. Idle,et al.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. , 1982, British medical journal.

[6]  J. P. Long,et al.  Hepatotoxicity following treatment with perhexiline maleate. , 1980, Irish medical journal.

[7]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[8]  P. Prudhomme de Saint-Maur,et al.  Perhexiline maleate-associated hepatic injury prevalence and characteristics. , 1980, Digestion.

[9]  D. Taylor,et al.  Liver damage due to perhexiline maleate. , 1979, Journal of clinical pathology.

[10]  M. Kew,et al.  Liver damage associated with perhexiline maleate. , 1979, Gut.

[11]  M Bichara,et al.  Perhexiline maleate-induced cirrhosis. , 1979, Gastroenterology.

[12]  J. Idle,et al.  Polymorphism of carbon oxidation of drugs and clinical implications. , 1978, British medical journal.

[13]  P. Paliard,et al.  Perhexiline maleate-induced hepatitis. , 1978, Digestion.

[14]  J. Hauw,et al.  Inclusions polymorphes diffuses chez un malade traité par le maléate de perhexiline. , 1978 .

[15]  C. Lenoir,et al.  Hépatites dues au maléate de perhexiline. , 1978 .

[16]  M. Beaugrand,et al.  [Hepatic lesions due to perhexiline maleate (author's transl)]. , 1978, Gastroenterologie clinique et biologique.

[17]  A. Floquet,et al.  [Ultrastructural study of the liver after treatment with perhexiline maleate]. , 1977, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[18]  C. Houdent,et al.  LIVER DURING PERHEXIUNE HYPOGLYCÆMIA , 1977, The Lancet.

[19]  M. Beaugrand,et al.  [Hepatitis due to perhexiline maleate. Development of cirrhosis after interruption of the drug. Report of two cases (author's transl)]. , 1977, Gastroenterologie clinique et biologique.

[20]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[21]  Stentiford Nh.  Perhexiline maleate toxicity: a case of severe jaundice. , 1977 .

[22]  F. Rosenthal,et al.  Proximal myopathy after perhexiline maleate treatment. , 1977, British medical journal.

[23]  G. Mcdonald.  LIVER DAMAGE AFTER PERHEXILINE MALEATE , 1977, The Lancet.

[24]  C. Houdent,et al.  Liver during perhexiline hypoglycaemia. , 1977, Lancet.

[25]  M. Eastwood,et al.  Letter: Neutrophil function and myeloperoxidase activity in inflammatory bowel disease. , 1976, Lancet.

[26]  P. Bouche,et al.  [Peripheral neuropathies caused by perhexiline maleate. Apropos of 7 cases]. , 1976, Coeur et medecine interne.

[27]  C. Forattini,et al.  [Perhexiline maleate in the treatment of angina pectoris]. , 1976, Minerva cardioangiologica.

[28]  Long-term perhexiline maleate and liver function. , 1976, British medical journal.

[29]  F. L. Gall,et al.  Hépatite toxique sub-aiguë et maléate de perhexilline , 1976 .

[30]  M. Beaugrand.  Hépatite médicamenteuse à la perhexilline , 1976 .

[31]  R. Lambert,et al.  Hépatite toxique subaiguë après traitement par maléate de perhexiline , 1976 .

[32]  Armstrong Ml.  Proceedings: A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. , 1973 .

[33]  Newberne Jw.  Proceedings: Assessment of safety data from patients on short and long-term perhexiline therapy. , 1973 .

[34]  L. Re,et al.  Proceedings: Clinical evaluation of perhexiline maleate in patients with angina pectoris associated with a positive coronary artery disease index. , 1973 .

[35]  J. F. Lang,et al.  Proceedings: The absorption, excretion and metabolism of perhexiline maleate by the human. , 1973, Postgraduate medical journal.

[36]  T. Peirce,et al.  Proceedings: Long-term assessment of perhexiline maleate in angina pectoris. , 1973, Postgraduate medical journal.

[37]  N. Gitlin,et al.  Proceedings: Perhexiline maleate in the treatment of angina pectoris: a double-blind trial. , 1973, Postgraduate medical journal.

[38]  G. Oriani,et al.  Proceedings: Perhexiline versus prenylamine. A controlled clinical trial in coronary insufficiency. , 1973, Postgraduate medical journal.

[39]  J. Newberne.  Proceedings: Assessment of safety data from patients on short and long-term perhexiline therapy. , 1973, Postgraduate medical journal.

[40]  R. Lewis,et al.  Proceedings: Clinical evaluation of perhexiline maleate in patients with angina pectoris associated with a positive coronary artery disease index. , 1973, Postgraduate medical journal.

[41]  C. Lieber,et al.  The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. , 1972, The Journal of pharmacology and experimental therapeutics.

[42]  M. Epstein,et al.  DEATHS IN THE COMMUNITY. , 1964, Lancet.

[43]  J. Donelan.  CASES of LUPUS TREATED by MEANS of TUBERCULIN, COMBINED with OTHER MEASURES , 1893, British medical journal.